Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LXEO
Strong SellSinkerLexeo Therapeutics, Inc. · Healthcare · United States · $399M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Lexeo Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing therapies for genetically defined cardiovascular, CNS, and other rare diseases. It utilizes a proprietary AAV gene therapy platform to target specific genetic defects, aiming to deliver one-time corrective treatments. The company is a specialized biotech company innovating in the gene therapy space, focusing on precision medicine for serious and often debilitating conditions.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.7M | 0.7M | 0 | 0 | 0 | -60.5% | — | — | 6.1M | 56.4% |
| EPS | -2.01 | -0.75 | -4.21 | -1.30 | -1.86 | — | -0.88 | -1.20 | -1.38 | — |
| Shares | 25.2M | 78.5M | 78.5M | 78.5M | 73.0M | +190.0% | 82.0M | — | — | — |
| Debt | 0 | 13.5M | 11.6M | 9.9M | 7.9M | -16.4% | 6.8M | — | — | — |
| Equity | -55.6M | -113.0M | 113.5M | 116.8M | 246.7M | 47.4% | — | — | — | — |
| Op CF | -44.2M | -54.6M | -59.5M | -81.2M | -98.6M | — | -88.4M | — | — | — |
| Inv CF | -0.2M | -0.9M | -0.2M | -94.1M | -90.3M | — | — | — | — | — |
| Fin CF | 150.9M | 0.2M | 103.8M | 88.8M | 216.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LXEO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LXEO | Lexeo Therapeutics, Inc.(you) | $399M | 7 | Strong Sell |
| FHTX | Foghorn Therapeutics Inc. | $356M | 7 | Strong Sell |
| UPB | Upstream Bio, Inc. | $366M | 8 | Strong Sell |
| LYEL | Lyell Immunopharma, Inc. | $356M | 7 | Strong Sell |
| CMPX | Compass Therapeutics, Inc. | $432M | 5 | Strong Sell |
| EVMN | Evommune, Inc. | $480M | 8 | Strong Sell |
| GALT | Galectin Therapeutics Inc. | $405M | 11 | Strong Sell |
| RCKT | Rocket Pharmaceuticals, Inc. | $424M | 10 | Strong Sell |
| STRO | Sutro Biopharma, Inc. | $339M | 9 | Strong Sell |
| KYTX | Kyverna Therapeutics, Inc. | $518M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%